In recent trading session, Xilio Therapeutics Inc (NASDAQ:XLO) saw 1.42 million shares changing hands at last check today with its beta currently measuring -0.24. Company’s recent per share price level of $0.96 trading at -$0.1 or -9.28% at last check today assigns it a market valuation of $44.00M. That most recent trading price of XLO’s stock is at a discount of -101.04% from its 52-week high price of $1.93 and is indicating a premium of 44.79% from its 52-week low price of $0.53.
For Xilio Therapeutics Inc (XLO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.22 in the current quarter.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Upright in the red during last session for losing -9.28%, in the last five days XLO remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $0.96 price level, adding 26.15% to its value on the day. Xilio Therapeutics Inc’s shares saw a change of 0.69% in year-to-date performance and have moved -25.46% in past 5-day. Xilio Therapeutics Inc (NASDAQ:XLO) showed a performance of 8.03% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 86.29% to its recent value today. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -629.17% in reaching the projected high whereas dropping to the targeted low would mean a loss of -629.17% for stock’s current value.
Xilio Therapeutics Inc (XLO) estimates and forecasts
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.3M for the same. And 2 analysts are in estimates of company making revenue of 23.9M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -44.91% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 59.04% while estimates for its earnings growth in next 5 years are of 39.65%.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the top institutional holder at XLO for having 3.79 million shares of worth $3.59 million. And as of 2024-06-30, it was holding 13.5618 of the company’s outstanding shares.
The second largest institutional holder is ROCK SPRINGS CAPITAL MANAGEMENT LP, which was holding about 3.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.7595 of outstanding shares, having a total worth of $2.85 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 739.56 shares of worth $0.71 million or 1.68% of the total outstanding shares. The later fund manager was in possession of 180.18 shares on Dec 31, 2024, making its stake of worth around $0.17 million in the company or a holder of 0.41% of company’s stock.
